Merck and Moderna initiate phase 3 study of NSCLC treatment
Betsy Goodfellow | December 13, 2023 | News story | Medical Communications | Merck, Moderna, NSCLC, Oncology, clinical trial
Merck (known as MSD outside of the US and Canada) and Moderna have announced the initiation of the phase 3 INTerpath-002 trial, which aims to asses V940, an investigational individualised neoantigen therapy (INT) in combination with Keytruda for the treatment of patients with completely resected stage 2, 3a or 3b (with nodal involvement) non-small cell lung cancer (NSCLC).
Recruitment for the trial has now begun, and the first patients have been enrolled in Australia.
Dr Marjorie Green, senior vice president and head of late-stage oncology, global clinical development at Merck, commented: “As lung cancer is the leading cause of cancer death worldwide, there is a need for continued scientific advancements to help fight this disease at earlier stages when patients have the best chance for better outcomes. By combining Keytruda with V940 (mRNA-4157), a promising new modality, we are researching innovative new approaches for earlier stage non-small cell lung cancer.”
Kyle Holen MD, Moderna’s senior vice president and head of development, therapeutics and oncology, added: “Addressing lung cancer reflects the constant struggle between medical innovation and biological complexity. Each patient’s cancer presents a labyrinth of genetic mutations, driving a novel approach of individualized medicines manufactured based on the distinct molecular tumor profile for each patient. We believe an individualised neoantigen therapy can be this catalyst for innovation and drive us forward towards the next frontier of cancer care. I’m incredibly thankful for the patients, investigators, and clinical trial sites for helping us in this mission.”
Betsy Goodfellow
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
